Intelligence Feed event · Macro · 2026-10-01

    Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial

    Question

    Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial

    Direct answer

    Boehringer Ingelheim and partner Zealand Pharma reported top-line results from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants receiving the dual glucagon/GLP-1 agonist achieved up to 13.1% body weight reduction compared to 3.1% in the placebo group, accompanied by markers of improved glycemic regulation.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-delivers-up-to-13-1-weight-loss-in-phase-iii-trial-d0cdfe

    MACRO
    Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial
    Boehringer Ingelheim and partner Zealand Pharma reported top-line results from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants receiving the dual glucagon/GLP-1 agonist achieved up to 13.1% body weight reduction compared to 3.1% in the placebo group, accompanied by markers of improved glycemic regulation.
    ZLDPY
    Impact
    76
    OCT 1
    SIG
    92%
    ZLDPY
    Survodutide Delivers Up to 13.1% Weight Loss in Phase III Trial
    Boehringer Ingelheim and partner Zealand Pharma reported top-line results from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants receiving the dual glucagon/GLP-1 agonist achieved up to 13.1% body weight reduction compared to 3.1% in the placebo group, accompanied by markers of improved glycemic regulation.
    → Statistically significant Phase III efficacy data improves commercialization probability and royalty revenue projections for co-developer ZLDPY.
    Impact
    Boehringer Ingelheim and partner Zealand Pharma reported top-line results from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants receiving the dual glucagon/GLP-1 agonist achieved up to 13.1% body weight reduction compared to 3.1% in the placebo group, accompanied by markers of improved glycemic regulation.
    Affected
    ZLDPY
    Transmission
    Statistically significant Phase III efficacy data improves commercialization probability and royalty revenue projections for co-developer ZLDPY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYroyalty and milestone revenue from Phase III clinical successUp1-5dZealand Pharma co-develops survodutide with Boehringer Ingelheim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month